POEM (Practice Of Embracing Each Moment) STUDY

Cancer Clinical Trial

— POEM  

Official title:

A Pilot Study of a Mobile/Online-based Mindfulness Intervention for Cancer Patients and Caregivers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03078608
• Other study ID #: CN-17-2851
• Status: Completed
• Phase: N/A
• Start date: October 24, 2017
• Est. completion date: November 8, 2018

Study information

• Verified date: December 2018
• Source: Kaiser Permanente
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A cancer diagnosis is extremely stressful, emotionally challenging, and often life-altering for both patients and their loved ones. Although more than one-third of patients experience distress, doctors are typically at a loss as to how to help patients and their families manage these emotional challenges. Mindfulness-based programs, including meditation, are offered at major medical centers in the US and have been found to help reduce stress and improve quality of life among cancer patients. However, these classes often require 30+ hours of in-person instruction over 8 weeks, which is neither practical nor feasible for patients undergoing chemotherapy due to side effects and scheduling conflicts.

This study will test whether an 8-week mobile app-based mindfulness program is accepted and useful for patients who have recently received chemotherapy and their loved ones. It will also test whether it is feasible to randomize participants into three groups: intervention, active control (receiving progressive muscle relaxation through the same app) and a wait list control group (will receive the meditation intervention 8 weeks later), so that a future study can test whether mindfulness intervention can help reduce stress and improve quality of life. Because many Americans own smartphone or tablet, an app that can teach stress reduction techniques at home or at infusion clinics has great potential to address emotional needs that providers often cannot.

The study will also include caregivers of patients who have recently received chemotherapy as research has shown that caregivers tend to show high levels of stress and depression and worse physical health compared to non-caregivers. The negative effects of caregiving are most pronounced in caregivers of patients with cancer. However, little support is directed to caregivers as most medical attention goes toward the patients. The patient-caregiver relationship may serve as a source of mutual support and a surrogate for community, which is traditionally considered to be an essential ingredient for sustaining mindfulness practices.

If this study is successful, it will justify a larger trial to determine if use of a mindfulness app is effective in reducing stress and improving quality of life for cancer patients and caregivers. If effective, this low-cost stress reduction strategy could be distributed and used for all types and stages of cancer patients and their caregivers, anywhere, any time, helping to improve the quality of life of the many individuals affected by cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: November 8, 2018
• Est. primary completion date: November 8, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• active member of Kaiser Permanente Northern California

• a diagnosis of cancer, and currently undergoing chemotherapy or completed chemotherapy in the past 6 months at time of recruitment

• English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet

• Caregivers: a partner, other family member, or a close friend who identify him/herself as the patient's primary unpaid caregiver. English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet access

Exclusion Criteria:

• Deafness

• severe mental illness

• Hospital Anxiety and Depression Scale score <8 or >14 on either anxiety or depression scale (patient only)

• current stress reduction practice

Related Conditions & MeSH terms

• Cancer
• Chemotherapy Effect
• Distress

Intervention

Behavioral:
• Mindfulness meditation program (administered via mobile app)
Mobile app-based/online mindfulness meditation program
• Progressive muscle relaxation (via mobile app)
Mobile app-based/online progressive muscle relaxation program

Locations

Country	Name	City	State
United States	Kaiser Permanente Northern California	Oakland	California

Sponsors (2)

Lead Sponsor	Collaborator
Kaiser Permanente	American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in anxiety and depression	The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression. This scale is frequently used to assess psychosocial outcomes in cancer patients. The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety. Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms.	Baseline to 8 weeks
Primary	Change in anxiety and depression	The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression. This scale is frequently used to assess psychosocial outcomes in cancer patients. The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety. Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms.	Baseline to 16 weeks
Secondary	Change in distress	The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level. Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress".	Baseline to 8 weeks
Secondary	Change in distress	The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level. Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress".	Baseline to 16 weeks
Secondary	Change in fatigue	The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale. A global fatigue score is calculated by averaging all items (ranging from 0 to 10). A higher score represents greater severity and impact of fatigue.	Baseline to 8 weeks
Secondary	Change in fatigue	The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale. A global fatigue score is calculated by averaging all items (ranging from 0 to 10). A higher score represents greater severity and impact of fatigue.	Baseline to 16 weeks
Secondary	Change in Pain	The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.	Baseline to 8 weeks
Secondary	Change in Pain	The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.	Baseline to 16 weeks
Secondary	Change in sleep quality	The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness.	Baseline to 8 weeks
Secondary	Change in sleep quality	The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness.	Baseline to 16 weeks
Secondary	Change in mindfulness	Mindfulness will be measured using the Five Facet Mindfulness Questionnaire	Baseline to 8 weeks
Secondary	Change in mindfulness	Mindfulness will be measured using the Five Facet Mindfulness Questionnaire	Baseline to 16 weeks
Secondary	Change in Post Traumatic Growth	Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory.	Baseline to 8 weeks
Secondary	Change in Post Traumatic Growth	Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory.	Baseline to 16 weeks